Molecule to Market: Inside the outsourcing space

The biologic CDMO growth guy

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Roger Lias, Chief Executive Officer at Stelis Biopharma. A fellow-Brit, Roger is a graduate of the University of Southampton. He also holds a PhD in Biotechnology from the University of Cambridge. His experience of the biopharma CDMO space in particular spans over 30 years including roles with the likes of Lonza, Diosynth, KBI Biopharma, Cytovance Biologics, Eden Biodesign, Allergen and Avid Bioservices and of course, Stelis. During the early part of his career, he moved to North America and now lives in California. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole load more) with Roger, covering an incredible 30 year journey at the heart of the biologic drug development explosion, including roles with the 'who’s who' of large molecule CDMOs. Roger speaks about what it was like creating a biologics CMO from the ground-up in the 90s with no obvious market. Raman and Roger discuss the value of being curious, energetic, open-minded and simply building relationships as the pillars to a long, successful career in the outsourcing space. Lastly, Roger speaks on the trend towards a closer collaboration between CDMO competitors, after all, nobody can do everything.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Leading M&A at a top-5 global CDMO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Quick, Executive Vice President, Corporate Development at Recipharm. In the decade that Mark and Raman have known each other, Mark has risen from a BD role in a small Swedish CMO, to becoming one of the key leaders in a business that has transitioned into becoming one of the top global CDMOs, where Mark has spearheaded the M&A deals. A graduate in Industrial Studies, Mark also did an MBA before joining Recipharm in 2006. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest (and a whole loaf more) with Mark as he explains what it’s been like growing a company from 600 - 9000 people, lifting the lid on CDMO M&A deals (having done 20+ transactions over the past 14 years), who gets involved, red flags to look out for and when you just know it’s a good fit. Mark explains how investing in relationships, embracing diversity and being open to new connections has helped him propel his career in the outsourcing space. He speaks about COVID-19 and how it has impacted a global CDMO in its different phases, including the operational impact of having sites in India and Italy. Lastly, Mark and Raman discuss continued consolidation in the sector and the increasing demand for sterile drug products with supply constraints and COVID-19 vaccines jumping the line.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The virotherapy virtuoso

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stefan Beyer, President and Managing Director at Vibalogics and Tom Hochuli, Chief Executive Officer at Vibalogics. Who is this dynamic duo you ask? Stefan has spent the bulk of his career in the vaccines and biologics space. He has been head of Vibalogics for almost 13 years, steering the company from a local startup, to global CDMO and world leader in the production of virotherapy products and oncolytic vaccines. Tom has over 25 years experience in the sector and prior to Vibalogics, he headed the cell and gene therapy operations for Lonza Houston. Today, Tom is responsible for Vibalogics’ U.S. expansion plans as the company sets its sights on developing a late phase and commercial virus manufacturing facility on the East Coast, U.S.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guests Stefan and Tom, covering the boom in virotherapy capabilities such as oncolytic viruses, viral vector gene therapies and viral vector vaccines over the past decade. Tom discusses the lessons he’s learned from being a platoon leader in the US Army to leading teams in business. Tom and Stefan explain how as a leader, it is important to have an open mind when it comes to exploring new opportunities and ideas and accepting failure as a part of success and learning. Lastly we explore the short-term impact that Covid-19 has had on delaying promising pipelines and compounds currently in clinical trials. We look ahead to the longer-term impact it will have on refocusing drug developers’ attention on the need for vaccines, and being better prepared in the case of an infectious outbreak. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Roundtable: Collaboration and driving efficiency

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Dexter Tjoa, Chief Executive Officer at Tjoapack, Erik Haeffler, VP Manufacturing Services & Head of Sustainability at Recipharm AB, John Ross, President at Mayne Pharma and Metrics Contract Services, and Mark Emalfarb, CEO, Board Member and Founder at Dyadic International, Inc.

During this discussion we will explore two angles to driving efficiency, diversification vs. development of specialism. Emerging trends include the move to manufacture multiple technologies under one roof, at the other end of the scale we see companies staying true to original areas of expertise in order to refine and grow.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences. 

Roundtable: Latest trends in CDMO

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Roger Lias Chief Executive Officer at Stelis Biopharma Pvt. Ltd. and Stelis Biopharma LLC, Mark Quick, Executive Vice President Corporate Development at Recipharm AB, Lynn Allen, Vice President Of Business Development at MedPharm Ltd, Alfredo Gomez, Head of Site at Idifarma, and Rick Seibert, Sr. Vice President, Innovation and Technology Services at Sharp Clinical Services.

This session will involve a wider discussion around COVID-19 related trends and also natural progression in the CDMO space. We will begin by exploring recurring trends involving futureproofing and digitisation across the industry including a growing need for automation.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Roundtable: Clinical trials in 2020 and beyond

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Torkel Gren, Senior Director, Technology Officer & Strategic Investments at Recipharm, Sascha Sonnenberg, Global Head of Business Development at Sharp Clinical Services, Vincent Dunne, CEO at Wasdell Group and Stephen Rode, Business Development Manager for Lonza Pharma and Biotech.

We’ll explore the impact of COVID-19 on traditional clinical trial processes to highlight how the industry has adapted. We will cover topics including ‘direct to patient treatment’ and trends that highlight a move away from the ‘norm’ in order to survive and thrive.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Roundtable: Global geography and the pharma and bio supply chain

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Erik Haeffler, VP Manufacturing Services & Head of Sustainability at Recipharm AB, Dan Stanton, Founder and Editor of Bioprocess Insider and Stefano Console, Senior Advisor and Founder at Oriento.

Join us as we discuss the impact of COVID-19 on the pharma and bio supply chain. We explore the real human challenges experienced in the face of a global pandemic and the impact these challenges have had on business. We also discuss concerns around safety and environmental impacts relating to materials suppliers.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Scientist & champion powerlifter

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Shane Needham, Chief Founding Scientist, Director of the Board and Owner at Alturas Analytics, Inc. With a PHD in chemistry, Dr. Needham has spent almost 30 years in the sector. He started his career at Pfizer and went on to found his own company, Alturas Analytics, which focuses on solving complex bioanalytical problems. He has over 100 publications and external presentations in the area of LC/MS and leads a team of world class scientists. And if this isn’t impressive enough, beyond work, Shane is a podcaster, TEDx motivational speaker, champion bodybuilder, champion powerlifter and philanthropist. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole loaf more) with Shane, covering the importance of coaching as a leader and setting the best example you can. Shane gives listeners life lessons in relationships, giving it your all, and in succeeding and failing. Raman and Shane speak about the impact of Covid-19 in accelerating the ‘things that would have happened eventually’ in the pharma and biotech analytical testing space. And finally Shane speaks on the parallels between success in business and success in hobbies, we’ll give you a hint, consistency is the most important factor.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

From fax to SaaS: digitising the the pharma supply chain

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason Lacombe, CEO at Veratrak. A graduate of Toronto and Oxford University, Jason was recently named as one of Forbes 30 Under 30 and has also advised the WHO and EU. Today, his business is one of the fastest growing tech companies in the life science space.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering the impact Covid-19 has had on accelerating the digitisation of the global pharmaceutical supply chain. Jason speaks about dealing with inertia and how it is now more clear than ever; the old way of doing things is not fit for our modern world. Lastly, Jason touches on the importance of aiming for less stock outs, faster leader times, more secure documentation and most importantly, better patient outcomes. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Successful outsourcing partnerships: now and then

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics. To say Mary has an impressive track record is an understatement. Across the last three decades she has worked for some of the biggest pharmaceutical companies in the world including Janssen and Bristol Myers Squibb before moving onto several fast growing biotech companies including Ironwood, Cyclerion and now Lyndra in senior regulatory and quality roles. She’s also a guest lecturer, a mentor to many, and a trustee for the Center for Great Expectations in New Jersey. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Mary Christian. In this episode, Mary reflects on the main differences in working with small, nimble bio and pharma companies compared to larger more structured organizations, particularly commenting on the different ways vendors are selected. She also addressed the major shift in types of relationships sponsors and vendors have with each other as she has seen things become less transactional over time. She gives valuable advice to vendors on how to get the most out of your partnership from the very beginning while explaining what a good and bad partnership experience looks like from her perspective as a sponsor. Mary gives advice based on her experience as a successful leader in the space and explains the value in having a support system at work and at home. She also highlights how important it is, for women especially, to not opt out of opportunities to further their career. Lastly Mary speaks about The Center for Great Expectations, an organization which empowers women and families battling mental health and substance disorders to break the cycle and provide better lives for their children.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.